-
2025
Leadgene® Indoxyl Sulfate (IS) ELISA Kit Receives HSA Approval as an IVD Product in Singapore
-
Successful Registration of Key Products in US FDA DMF
-
Leadgene Biomedical, Inc. has successfully completed the acquisition of 100% equity in SIDSCO.
-
2024
〝Leadgene〞Indoxyl Sulfate (IS) ELISA Kit Awarded the 2024 Symbol of National Quality (SNQ)
-
〝Leadgene〞Indoxyl Sulfate (IS) ELISA Kit has obtained Marketing Authorization Code (MAC) in Vietnam
-
Tripartite collaboration with CYTENA BPS and CYTENA to establish an innovative automated cell line development platform
-
IS ELISA Kit has received IVD certification (MOHW-MD-No. 007625) from the Taiwan Food and Drug Administration (TFDA)
-
China Patent Was Granted on January 24th, 2024. Patent No. CN 111741974 B
-
2023
2023 Best Bio CEO Second Prize & Best Potential Prize
-
2023 Taipei Biotech Awards - Innovation Awards Special Mention Awards
-
Japan Patent Was Granted on September 13th, 2023. Japan Patent No. P2020-558504
-
Earned Recognition as a Biotech and Pharmaceutical Company. Paving the Way for Advanced Kidney Disease Diagnostics in Taiwan
-
US Patent Was Granted on January 24th, 2023. US Patent No. 11,560,423
-
2022
31st National Award of Outstanding SMEs
-
2022 Taiwan BIO Awards - Emerging Company of the Year
-
2021
18th National Innovation Award, Ministry of Science and Technology
-
2021 PTRD Gold medal awarded, Ministry of Health and Welfare‧Ministry of Economics, Pharmaceutical Technology & Research Development (PTRD) Award
-
Leadgene Biomedical Obtains the Registration Certification of Foreign in vitro Diagnostic Manufacturer in Japan
-
Approval for Starting a New Division in Tainan Science Park, Southern Taiwan Science Park, Taiwan
